Hypertension Management in Peripheral Artery Disease: A Mini Review | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Hypertension Management in Peripheral Artery Disease: A Mini Review

Author(s): A. Kharawala, S. Nagraj, S. Pargaonkar, J. Seo, D.G. Kokkinidis* and S.E. Altin

Volume 20, Issue 1, 2024

Published on: 11 December, 2023

Page: [1 - 9] Pages: 9

DOI: 10.2174/0115734021267004231122061712

Price: $65

Abstract

Lower extremity peripheral artery disease (PAD) affects over 230 million adults globally, with hypertension being one of the major risk factors for the development of PAD. Despite the high prevalence, patients with hypertension who have concomitant PAD are less likely to receive adequate therapy. Through this review, we present the current evidence underlying hypertension management in PAD, guideline-directed therapies, and areas pending further investigation. Multiple studies have shown that both high and relatively lower blood pressure levels are associated with worse health outcomes, including increased morbidity and mortality. Hence, guideline-directed recommendation involves cautious management of hypertensive patients with PAD while ensuring hypotension does not occur. Although any antihypertensive medication can be used to treat these patients, the 2017 American Heart Association/American College of Cardiology (AHA/ACC), 2017 European Society of Cardiology (ESC), and 2022 Canadian guidelines favor the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) as the initial choice. Importantly, data on blood pressure targets and treatment of hypertension in PAD are limited and largely stem from sub-group studies and post-hoc analysis. Large randomized trials in patients with PAD are required in the future to delineate hypertension management in this complex patient population.

Keywords: Hypertension, peripheral artery disease, systolic blood pressure, diastolic blood pressure, guideline-based management, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker.

Graphical Abstract

[1]
Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. Circ Res 2015; 116(9): 1527-39.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303566 ] [PMID: 25908726]
[2]
Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: A literature review. Cardiovasc Ther 2019; 2019: 1-9.
[http://dx.doi.org/10.1155/2019/8295054 ] [PMID: 32099582]
[3]
Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis. Lancet Glob Health 2019; 7(8): e1020-30.
[http://dx.doi.org/10.1016/S2214-109X(19)30255-4 ] [PMID: 31303293]
[4]
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral Artery Disease: Executive summary. J Am Coll Cardiol 2017; 69(11): 1465-508.
[http://dx.doi.org/10.1016/j.jacc.2016.11.008] [PMID: 27851991]
[5]
Kokkinidis DG, Armstrong EJ. Current developments in endovascular therapy of peripheral vascular disease. J Thorac Dis 2020; 12(4): 1681-94.
[http://dx.doi.org/10.21037/jtd.2019.12.130] [PMID: 32395311]
[6]
Aday AW, Matsushita K. Epidemiology of peripheral artery disease and Polyvascular Disease. Circ Res 2021; 128(12): 1818-32.
[http://dx.doi.org/10.1161/CIRCRESAHA.121.318535 ] [PMID: 34110907]
[7]
Criqui MH, Matsushita K, Aboyans V, et al. Lower extremity peripheral Artery Disease: Contemporary epidemiology, management gaps, and future directions: A scientific statement from the american heart association. Circulation 2021; 144(9): e171-91.
[http://dx.doi.org/10.1161/CIR.0000000000001005 ] [PMID: 34315230]
[8]
Olin JW, Sealove BA. Peripheral artery disease: Current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010; 85(7): 678-92.
[http://dx.doi.org/10.4065/mcp.2010.0133] [PMID: 20592174]
[9]
Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg 2010; 51(1): 230-41.
[http://dx.doi.org/10.1016/j.jvs.2009.08.073] [PMID: 20117502]
[10]
Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R. Critical limb ischemia: Current challenges and future prospects. Vasc Health Risk Manag 2018; 14: 63-74.
[http://dx.doi.org/10.2147/VHRM.S125065] [PMID: 29731636]
[11]
Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The Strong Heart Study. Circulation 2004; 109(6): 733-9.
[http://dx.doi.org/10.1161/01.CIR.0000112642.63927.54 ] [PMID: 14970108]
[12]
Im SI, Rha SW, Choi BG, et al. Impact of uncontrolled hypertension on 12-month clinical outcomes following below-the-knee arteries (BTK) interventions in patients with critical limb ischemia. Clin Hypertens 2015; 22(1): 9.
[http://dx.doi.org/10.1186/s40885-016-0044-y] [PMID: 26929823]
[13]
Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010; 55(1): 48-53.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.142240] [PMID: 19996066]
[14]
Lu Y, Ballew SH, Tanaka H, et al. 2017 ACC/AHA blood pressure classification and incident peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) Study. Eur J Prev Cardiol 2020; 27(1): 51-9.
[http://dx.doi.org/10.1177/2047487319865378] [PMID: 31362534]
[15]
Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012; 308(16): 1660-7.
[http://dx.doi.org/10.1001/jama.2012.13415] [PMID: 23093164]
[16]
Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180-9.
[http://dx.doi.org/10.1001/jama.295.2.180] [PMID: 16403930]
[17]
Meijer WT, Grobbee DE, Hunink MGM, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: The Rotterdam study. Arch Intern Med 2000; 160(19): 2934-8.
[http://dx.doi.org/10.1001/archinte.160.19.2934] [PMID: 11041900]
[18]
Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2007; 55(4): 583-9.
[http://dx.doi.org/10.1111/j.1532-5415.2007.01123.x ] [PMID: 17397438]
[19]
Curry SJ, Krist AH, Owens DK, et al. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index. JAMA 2018; 320(2): 177-83.
[http://dx.doi.org/10.1001/jama.2018.8357] [PMID: 29998344]
[20]
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery Disease: Executive summary: A report of the american college of cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017; 135(12): e686-725.
[http://dx.doi.org/10.1161/CIR.0000000000000470 ] [PMID: 27840332]
[21]
Krishnamurthy V, Munir K, Rectenwald JE, et al. Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. Vasc Med 2014; 19(6): 491-9.
[http://dx.doi.org/10.1177/1358863X14552013] [PMID: 25292418]
[22]
Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124(1): 17-23.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.003954 ] [PMID: 21690489]
[23]
Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. Vasc Med 2020; 25(2): 106-17.
[http://dx.doi.org/10.1177/1358863X19894055] [PMID: 31964311]
[24]
Welten GMJM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: A comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51(16): 1588-96.
[http://dx.doi.org/10.1016/j.jacc.2007.11.077] [PMID: 18420103]
[25]
Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 3(2): e000697.
[http://dx.doi.org/10.1161/JAHA.113.000697] [PMID: 24721799]
[26]
McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12(4): 209-15.
[http://dx.doi.org/10.1007/s11606-006-5042-4] [PMID: 9127224]
[27]
Ya’qoub L, Peri-Okonny P, Wang J, Patel KK, Stone N, Smolderen K. Blood pressure management in patients with symptomatic peripheral artery disease: insights from the PORTRAIT registry. Eur Heart J Qual Care Clin Outcomes 2019; 5(1): 79-81.
[http://dx.doi.org/10.1093/ehjqcco/qcy035] [PMID: 30020425]
[28]
Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials. PLoS One 2017; 12(6): e0178713.
[http://dx.doi.org/10.1371/journal.pone.0178713] [PMID: 28575088]
[29]
Shetty S, Malik AH, Feringa H, El Accaoui R, Girotra S. Meta-analysis evaluating calcium channel blockers and the risk of peripheral arterial disease in patients with hypertension. Am J Cardiol 2020; 125(6): 907-15.
[http://dx.doi.org/10.1016/j.amjcard.2019.12.026] [PMID: 31959429]
[30]
Frary JMC, Pareek M, Byrne C, et al. Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: The Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother 2021; 7(3): e38-40.
[http://dx.doi.org/10.1093/ehjcvp/pvaa102] [PMID: 32853332]
[31]
Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI. Association of blood pressure measurements with peripheral artery disease events. Circulation 2018; 138(17): 1805-14.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033348 ] [PMID: 29930023]
[32]
Emdin CA, Anderson SG, Callender T, et al. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. BMJ 2015; 351: h4865.
[http://dx.doi.org/10.1136/bmj.h4865] [PMID: 26419648]
[33]
Mao Y, Huang Y, Yu H, et al. Incidence of peripheral arterial disease and its association with pulse pressure: A prospective cohort study. Front Endocrinol 2017; 8: 333.
[http://dx.doi.org/10.3389/fendo.2017.00333] [PMID: 29225591]
[34]
Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008; 371(9631): 2219-21.
[http://dx.doi.org/10.1016/S0140-6736(08)60804-1 ] [PMID: 18561995]
[35]
Vishram JKK, Borglykke A, Andreasen AH, et al. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. Hypertension 2012; 60(5): 1117-23.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.201400] [PMID: 23006731]
[36]
Steppan J, Barodka V, Berkowitz DE, Nyhan D. Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract 2011; 2011: 1-8.
[http://dx.doi.org/10.4061/2011/263585] [PMID: 21845218]
[37]
Levin MG, Klarin D, Walker VM, et al. Association between genetic variation in blood pressure and increased lifetime risk of peripheral artery disease. Arterioscler Thromb Vasc Biol 2021; 41(6): 2027-34.
[http://dx.doi.org/10.1161/ATVBAHA.120.315482 ] [PMID: 33853351]
[38]
Aboyans V, Ricco JB, Bartelink MLEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[39]
Krogager ML, Pareek M, Kragholm KH, et al. Intensive vs. standard blood pressure control and vascular procedures: Insights from the systolic blood pressure intervention Trial (SPRINT). Eur Heart J Cardiovasc Pharmacother 2021; 7(3): e35-7.
[http://dx.doi.org/10.1093/ehjcvp/pvaa093] [PMID: 32722801]
[40]
Fudim M, Jones WS. New curveball for hypertension guidelines? Circulation 2018; 138(17): 1815-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036409 ] [PMID: 30354668]
[41]
Golledge J, Fernando ME, Armstrong DG. Current management of peripheral artery Disease: Focus on pharmacotherapy. Drugs 2022; 82(11): 1165-77.
[http://dx.doi.org/10.1007/s40265-022-01755-7] [PMID: 35960432]
[42]
Bevan GH, White Solaru KT. Evidence-based medical management of peripheral artery disease. Arterioscler Thromb Vasc Biol 2020; 40(3): 541-53.
[http://dx.doi.org/10.1161/ATVBAHA.119.312142 ] [PMID: 31996023]
[43]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension 2018; 71(6): e13-e115.
[PMID: 29133356]
[44]
Abola MTB, Golledge J, Miyata T, et al. Asia-pacific consensus statement on the management of peripheral artery disease: A report from the asian pacific society of atherosclerosis and vascular disease asia-pacific peripheral artery disease consensus statement project committee. J Atheroscler Thromb 2020; 27(8): 809-907.
[http://dx.doi.org/10.5551/jat.53660] [PMID: 32624554]
[45]
(a) Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019; 58(S1): S1-S109 e33..;
(b) Schizas CDG, Pargaonkar D, Karamanis S, et al. Differences between lower extremity arterial occlusion vs. stenosis and predictors of successful endovascular interventions. Medicina 2023; 59(11): 2029.;
(c) Ahmad Naser IS, Akunor H, Fatuyi M, et al. Short term outcomes of endovascular and surgical therapies for critical limb ischemia: a nationwide analysis. Circulation 2023; 148: 16822.
[46]
Verdecchia P. Prognostic value of ambulatory blood pressure: Current evidence and clinical implications. Hypertension 2000; 35(3): 844-51.
[http://dx.doi.org/10.1161/01.HYP.35.3.844 ] [PMID: 10720605]
[47]
Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 2002; 39(5): 878-85.
[http://dx.doi.org/10.1016/S0735-1097(01)01827-7 ] [PMID: 11869856]
[48]
Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020; 36(5): 596-624.
[http://dx.doi.org/10.1016/j.cjca.2020.02.086 ] [PMID: 32389335]
[49]
Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344(1): 3-10.
[http://dx.doi.org/10.1056/NEJM200101043440101 ] [PMID: 11136953]
[50]
Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334(7599): 885-8.
[http://dx.doi.org/10.1136/bmj.39147.604896.55] [PMID: 17449506]
[51]
Fakhry F, Rouwet EV, den Hoed PT, Hunink MGM, Spronk S. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg 2013; 100(9): 1164-71.
[http://dx.doi.org/10.1002/bjs.9207] [PMID: 23842830]
[52]
Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: Six-month outcomes from the claudication: Exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012; 125(1): 130-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.075770 ] [PMID: 22090168]
[53]
Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: The CLEVER study. J Am Coll Cardiol 2015; 65(10): 999-1009.
[http://dx.doi.org/10.1016/j.jacc.2014.12.043] [PMID: 25766947]
[54]
Sodium Intake for Adults and Children WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2015.
[55]
Feringa HHH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47(6): 1182-7.
[http://dx.doi.org/10.1016/j.jacc.2005.09.074] [PMID: 16545650]
[56]
Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1(1): 18-20.
[http://dx.doi.org/10.3317/jraas.2000.002] [PMID: 11967789]
[57]
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-59.
[http://dx.doi.org/10.1056/NEJMoa0801317] [PMID: 18378520]
[58]
Officers A. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-97.
[http://dx.doi.org/10.1001/jama.288.23.2981] [PMID: 12479763]
[59]
Singer DRJ, Kite A. Management of hypertension in peripheral arterial disease: Does the choice of drugs matter? Eur J Vasc Endovasc Surg 2008; 35(6): 701-8.
[http://dx.doi.org/10.1016/j.ejvs.2008.01.007] [PMID: 18375152]
[60]
Tran B. Assessment and management of peripheral arterial disease: What every cardiologist should know. Heart 2021; 107(22): 1835-43.
[http://dx.doi.org/10.1136/heartjnl-2019-316164] [PMID: 33985986]
[61]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34(28): 2159-219.
[http://dx.doi.org/10.1093/eurheartj/eht151] [PMID: 23771844]
[62]
Östergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25(1): 17-24.
[http://dx.doi.org/10.1016/j.ehj.2003.10.033] [PMID: 14683738]
[63]
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145-53.
[64]
Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med 2021; 384(3): 216-28.
[http://dx.doi.org/10.1056/NEJMoa2028220] [PMID: 33186492]
[65]
Abramson BL, Al-Omran M, Anand SS, et al. Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease. Can J Cardiol 2022; 38(5): 560-87.
[http://dx.doi.org/10.1016/j.cjca.2022.02.029] [PMID: 35537813]
[66]
Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med 2015; 20(3): 237-44.
[http://dx.doi.org/10.1177/1358863X15574321] [PMID: 25835349]
[67]
Carey RM, Whelton PK. Evidence for the universal blood pressure goal of <130/80 mm Hg is strong. Hypertension 2020; 76(5): 1384-90.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.14647] [PMID: 32951472]
[68]
Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B. Harmonization of the american college of cardiology/american heart association and european society of cardiology/european society of hypertension blood pressure/hypertension guidelines: Comparisons, reflections, and recommendations. Circulation 2022; 146(11): 868-77.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.054602 ] [PMID: 35950927]
[69]
Östergren J, Poulter NR, Sever PS, et al. The anglo-scandinavian cardiac outcomes trial: Blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008; 26(11): 2103-11.
[http://dx.doi.org/10.1097/HJH.0b013e328310e0d9 ] [PMID: 18854748]
[70]
Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med 2014; 29(11): 1475-83.
[http://dx.doi.org/10.1007/s11606-014-2947-1] [PMID: 25002161]
[71]
Hoogerbrugge N, de Groot E, de Heide LH, et al. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Neth J Med 2002; 60(9): 354-61.
[PMID: 12572707]
[72]
Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006; 24(11): 2163-8.
[http://dx.doi.org/10.1097/01.hjh.0000249692.96488.46] [PMID: 17053536]
[73]
Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane Libr 2013; (12): CD003075.
[http://dx.doi.org/10.1002/14651858.CD003075.pub3 ] [PMID: 24307487]
[74]
Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151(9): 1769-76.
[http://dx.doi.org/10.1001/archinte.1991.00400090063012 ] [PMID: 1679624]
[75]
Espinola-Klein C, Weisser G, Jagodzinski A, et al. Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011; 58(2): 148-54.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.169169] [PMID: 21646599]
[76]
Mirault T, Galloula A, Cambou JP, et al. Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease. Medicine 2017; 96(5): e5916.
[http://dx.doi.org/10.1097/MD.0000000000005916 ] [PMID: 28151868]
[77]
Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 2011; 29(7): 1448-56.
[http://dx.doi.org/10.1097/HJH.0b013e3283471151 ] [PMID: 21602713]
[78]
Paravastu SCV, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38(1): 66-70.
[http://dx.doi.org/10.1016/j.ejvs.2009.02.019] [PMID: 19359199]
[79]
Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D. Beta-blocker treatment does not worsen critical limb ischemia in patients receiving endovascular therapy. J Atheroscler Thromb 2015; 22(5): 481-9.
[http://dx.doi.org/10.5551/jat.27359] [PMID: 25445890]
[80]
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S5-S67.
[81]
Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164(4): 440-6.
[http://dx.doi.org/10.1001/archinte.164.4.440] [PMID: 14980996]
[82]
Khan SZ, O’Brien-Irr MS, Rivero M, et al. Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia. J Vasc Surg 2020; 72(6): 2130-8.
[http://dx.doi.org/10.1016/j.jvs.2020.02.041 ] [PMID: 32276021]

Rights & Permissions Print Cite
Article Metrics
36
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy